Zimmer Biomet Holdings, Inc. $ZBH Stock Acquired by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8,351.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,480 shares of the medical equipment provider’s stock after purchasing an additional 10,356 shares during the quarter. Fulcrum Asset Management LLP’s holdings in Zimmer Biomet were worth $957,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in Zimmer Biomet in the 2nd quarter valued at $1,344,282,000. State Street Corp lifted its holdings in shares of Zimmer Biomet by 0.6% during the second quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider’s stock worth $766,343,000 after buying an additional 52,044 shares in the last quarter. Primecap Management Co. CA acquired a new stake in shares of Zimmer Biomet during the second quarter worth $328,578,000. Dimensional Fund Advisors LP boosted its position in shares of Zimmer Biomet by 1.1% in the first quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider’s stock valued at $201,082,000 after acquiring an additional 24,208 shares during the period. Finally, Bank of America Corp DE bought a new stake in shares of Zimmer Biomet in the second quarter valued at about $187,480,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Zimmer Biomet

In other news, insider Chad Phipps sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the transaction, the insider directly owned 65,231 shares in the company, valued at approximately $6,415,468.85. The trade was a 4.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Kevin R. Thornal sold 5,691 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. Additional details regarding this sale are available in the official SEC disclosure. 1.28% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms recently commented on ZBH. JPMorgan Chase & Co. raised their price target on shares of Zimmer Biomet from $117.00 to $120.00 and gave the stock a “neutral” rating in a research report on Thursday, November 5th. Weiss Ratings raised shares of Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Stifel Nicolaus set a $125.00 price objective on shares of Zimmer Biomet in a report on Wednesday, November 4th. Canaccord Genuity Group increased their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. Finally, Truist Financial set a $114.00 target price on shares of Zimmer Biomet in a report on Thursday, November 5th. Seven equities research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus target price of $112.74.

Zimmer Biomet Stock Down 2.7%

Shares of NYSE ZBH opened at $104.56 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.79 and a current ratio of 1.46. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $112.54. The stock has a market capitalization of $19.79 billion, a P/E ratio of 26.47, a PEG ratio of 2.52 and a beta of 0.50. The stock’s fifty day moving average is $95.68 and its 200 day moving average is $92.48.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a return on equity of 13.02% and a net margin of 8.95%. The business had revenue of $2.06 billion during the quarter, compared to the consensus estimate of $2.04 billion. During the same quarter in the previous year, the firm earned $1.90 earnings per share. Zimmer Biomet’s revenue for the quarter was up 3.1% compared to the same quarter last year. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.56 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 24.30%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.